Elicio Therapeutics, Inc. (ELTX)
(Delayed Data from NSDQ)
$9.20 USD
+0.13 (1.43%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $9.19 -0.01 (-0.11%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ELTX 9.20 +0.13(1.43%)
Will ELTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELTX
Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?
ELTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know
All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy
Other News for ELTX
Elicio Therapeutics GAAP EPS of -$0.66
JonesTrading Sticks to Their Buy Rating for Elicio Therapeutics (ELTX)
Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate ...
Elicio Therapeutics (ELTX) Advances with Positive Interim Trial Review
Elicio announces positive recommendation by IDMC to continue ELI-002 Phase 2